Almirall, S.A. (0O9B.IL)
IOB - IOB Delayed price. Currency in EUR
Add to watchlist
As of 08:48AM BST. Market open.
| Previous close | 8.61 |
| Open | 8.68 |
| Bid | 8.45 x 0 |
| Ask | 8.82 x 0 |
| Day's range | 8.65 - 8.68 |
| 52-week range | 7.20 - 10.08 |
| Volume | |
| Avg. volume | 55,673 |
| Market cap | 1.969B |
| Beta (5Y monthly) | 0.40 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.18 (2.03%) |
| Ex-dividend date | 12 May 2023 |
| 1y target est | N/A |
- Investing.com
Almirall's Ebglyss poised for EU approval, challenging Sanofi and Regeneron’s Dupixent
Almirall, the Spanish pharmaceutical company, is on the brink of securing European Union (EU) approval for its IL-13 inhibitor lebrikizumab, marketed as Ebglyss, for atopic dermatitis treatment. The European Medicines Agency's (EMA) human medicines committee has recommended the drug's approval, setting up a challenge to the market-leading Dupixent, produced by Sanofi (NASDAQ:SNY) and Regeneron (NASDAQ:REGN).
© 2024 Yahoo. All rights reserved.